N/A
Completed N=54
tDCS to Decrease Opioid Relapse (UG3)
opioid dependence · Craving
Source: ClinicalTrials.gov NCT03842137 ↗
Enrolled (actual)
54
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcomePrimary: Opioid Craving — 8.92; 8.32 units on a scale — p=.008
Summary
In the current proposal, the investigators will measure behavioral and brain responses following transcranial direct current stimulation (tDCS) to the dorsolateral prefrontal cortex (DLPFC) (anode on right DLPFC, cathode on the left DLPFC) delivered during cognitive control network (CCN) priming. Participants with opioid dependence, in the first month of prescribed buprenorphine or methadone, will be assessed twice using electroencephalographic (EEG), once prior to tDCS+CCN priming and again at the completion of 5 sessions of tDCS+CCN priming (one week later). EEG will provide validation of expected changes in these networks following tDCS stimulation of the DLPFC.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Opioid Craving |
8.92; 8.32 | .008 sig |
| SECONDARY EEG Theta Brainwave Activity |
.38; .33 | .005 sig |
Eligibility Criteria
Inclusion Criteria
- current opioid dependence
- between 21-50 years of age
- recent initiation of buprenorphine or methadone (<30 days)
Exclusion Criteria
- current criteria for a DSM-V diagnosis of bipolar disorder, schizophrenia, schizo-affective, schizophreniform, or paranoid disorder
- current suicidality
- evidence of neurocognitive dysfunction
- contraindications for tDCS (e.g seizure disorder)
- probation/parole requirements or an upcoming move that might interfere with protocol participation
- planning to terminate buprenorphine in less than 3 months
- scalp lesions near the tDCS electrode sites
Data sourced from ClinicalTrials.gov (NCT03842137). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.